PPARGC1A and neoplasm: Clinical data are available on metabolism-related protein levels as biomarkers to determine the metabolic status of tumors, such as LDH, MCT1/4, PGC-1α, etc. Therefore, harnessing metabolic modulators to improve the tumor microenvironment based on the predicted results of metabolic modality will improve the efficacy of immunotherapy.